Form 4: TScan Therapeutics Director Granted 67,000 Options

Director Garry A. Nicholson received a grant of 67,000 stock options with a one-year vesting period, aligning board interests with shareholder value.

Summary

• Director Garry A. Nicholson was granted 67,000 stock options for TScan Therapeutics (TCRX) on May 20, 2026.
• The options carry an exercise price of $0.9946 per share.
• The grant is scheduled to vest in full on the earlier of May 20, 2027, or the date of the next annual meeting of stockholders.
• The options have a ten-year term, expiring on May 20, 2036.
• Following this transaction, the reporting person holds a total of 67,000 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative filing, confirming insider participation and alignment without signaling a major shift in corporate strategy.

Positives

• Insider alignment with shareholders through equity-based compensation.
• Long-term commitment shown by the ten-year expiration date of the options.
• Vesting is tied to continued service, ensuring board stability for at least the next year.

Negatives

• Potential for future share dilution upon the exercise of these 67,000 options.
• The exercise price of $0.9946 may indicate a low current valuation or a specific strike price strategy.

Risks

• Vesting is subject to the reporting person's continued service; a departure would result in forfeiture.
• The value of the options is entirely dependent on the future market price of TCRX exceeding the $0.9946 strike price.

Future Outlook

The filing indicates a standard annual equity grant for a director, suggesting a continuation of the current board structure and compensation policy through mid-2027.

Management Comments

• The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is standard in the biotechnology sector to preserve cash for research and development while incentivizing long-term stock performance.

Comparison to Industry Standards

• The grant size of 67,000 options is consistent with mid-cap biotechnology board compensation packages.
• A one-year cliff vesting schedule is a typical benchmark for annual director equity awards in Nasdaq-listed companies.
• The ten-year expiration term is the standard duration for incentive and non-qualified stock options in the U.S.

Corporate Governance

Related Party Transactions

• The grant of 67,000 stock options to Director Garry A. Nicholson is a related party transaction between the issuer and an insider.

Stakeholder Impact

• Shareholders may experience minor dilution upon exercise of the options.
• The board of directors maintains stability through the retention of Garry A. Nicholson.

Next Steps

• Full vesting of options on May 20, 2027, or the next annual meeting.

Key Dates

Keywords

TScan Therapeutics, TCRX, Insider Trading, Form 4, Stock Options, Director Compensation, Garry Nicholson, Biotechnology